Witzens-Harig, M., Memmer, M., Dreyling, M., & Hess, G. (2013). A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. BMC cancer, 13, . https://doi.org/10.1186/1471-2407-13-308
Chicago-Zitierstil (17. Ausg.)Witzens-Harig, Mathias, Marie-Luise Memmer, Martin Dreyling, und Georg Hess. "A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients with Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma - the STORM Trial." BMC Cancer 13 (2013). https://doi.org/10.1186/1471-2407-13-308.
MLA-Zitierstil (9. Ausg.)Witzens-Harig, Mathias, et al. "A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients with Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma - the STORM Trial." BMC Cancer, vol. 13, 2013, https://doi.org/10.1186/1471-2407-13-308.